MSD
Pembrolizumab/MK1308 or MK1308 + Lenvatinib or MK1308 + MK4830 or MK4280
Biodrugs/ Drugs
Cancer
Platform trial: Pembrolizumab in combination with Investigational Agents in PD-1/L1-refactory Extensive stage small cell lung Cancer in need of second-line therapy.
2Phase II in Spain,
1Phase I in Spain